Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10314959" target="_blank" >RIV/00216208:11110/15:10314959 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10314959

Výsledek na webu

<a href="http://dx.doi.org/10.1183/13993003.00364-2015" target="_blank" >http://dx.doi.org/10.1183/13993003.00364-2015</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1183/13993003.00364-2015" target="_blank" >10.1183/13993003.00364-2015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

Popis výsledku v původním jazyce

In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-nave incident and prevalent cohorts. Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (<= 6 months; n=110) or prevalent (>6 months; n=157). Therisk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression. The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and p

Název v anglickém jazyce

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN

Popis výsledku anglicky

In SERAPHIN, a long-term, randomised, controlled trial (NCT00660179) in pulmonary arterial hypertension (PAH), macitentan significantly reduced the risk of morbidity/mortality and PAH-related death/hospitalisation. We evaluated disease progression and the effect of macitentan in treatment-nave incident and prevalent cohorts. Patients allocated to placebo, or macitentan 3 mg or 10 mg were classified by time from diagnosis to enrolment as incident (<= 6 months; n=110) or prevalent (>6 months; n=157). Therisk of morbidity/mortality and PAH-related death/hospitalisation was determined using Cox regression. The risk of morbidity/mortality (Kaplan-Meier estimates at month 12: 54.4% versus 26.7%; p=0.006) and PAH-related death/hospitalisation (Kaplan-Meier estimates at month 12: 47.3% versus 19.9%; p=0.006) were significantly higher for incident versus prevalent patients receiving placebo, respectively. There was no significant difference in the risk of all-cause death between incident and p

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Respiratory Journal

ISSN

0903-1936

e-ISSN

—

Svazek periodika

46

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

1711-1720

Kód UT WoS článku

000366948700025

EID výsledku v databázi Scopus

2-s2.0-84949032805